The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Olifant Energy, LLC
Advised US Energy Development Corporation, a Texas-based, privately held oil and gas operator, on its acquisition of Olifant Energy Corporation, a Tulsa-based E&P company with operations in Ward County of the Delaware Basin
Atlas Technical Consultants
Advised Boxwood Merger Corp., a publicly-traded special purpose acquisition company, on its combination with Atlas Technical Consultants, a leading provider of professional testing, inspection, engineering and consulting services
EnerVest properties in the Utica Shale
Advised EnerVest Ltd., and its associated investment partnerships, on the sale of Utica Shale oil and gas properties across 12 counties in eastern Ohio to an entity controlled by Encino Acquisition Partners
Alloy Piping Products (“APP”)
Advised McDermott International, a premier, fully integrated provider of technology, engineering and construction solutions to the energy industry, on the sale of Alloy Piping Products (“APP”), the distribution and manufacturing arm of its US pipe fabrication business
80 Collins Precinct
Advised Dexus in relation to its acquisition of the 80 Collins precinct from QIC Global Real Estate
T5 Data Centers Strategic Partnership
Advised T5 Data Centers, a leading national data center owner and operator, on the creation of a fully integrated platform with QuadReal Property Group to develop, acquire and operate data centers via a $1.0 billion investment from QuadReal
Pfizer Inc. Consumer Health Business
Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture
Starpharma Holdings Limited, patented VivaGel BV® product
Advised Starpharma Holdings Limited on a US licensing agreement of its patented VivaGel BV® product with ITF Pharma, a US subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company
Aisthesis
Advised Aisthesis, a portfolio company of Triton Pacific Capital Partners, on its sale to NAPA, a portfolio company of American Securities
Montserrat Day Hospital Group
Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities
Common shares and common share purchase warrants in Canopy Growth
Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants
35% of Sabine Oil & Gas’ interest in oil and gas properties in East Texas
Advised Osaka Gas, a Japanese utility, on the acquisition of 35% of Sabine Oil & Gas’s interest in oil and gas properties located primarily in Harrison and Panola Counties, Texas
Campbell Global
Advised CatchMark Timber Trust, Inc. on its purchase of 1.1 million acres of East Texas timberlands from Campbell Global
Willbros Group, Inc.
Advised Willbros Group, Inc., a specialty energy infrastructure contractor serving the power and oil & gas industries, on its sale to Primoris Services Corporation
Pure Industrial Real Estate Trust
Advised the Special Committee of the Board of Trustees of Pure Industrial Real Estate Trust ("PIRET"), the largest pure-play industrial REIT in Canada, regarding the acquisition of PIRET by Blackstone Property Partners
CB&I
Advised McDermott International, Inc., a leading provider of integrated engineering, procurement, construction, installation and module fabrication services for upstream field developments worldwide, on its combination with CB&I, a leading provider of technology and infrastructure for the energy industry
Substantially all of the gas production and midstream assets of Energy Corporation of America
Advised Energy Corporation of America, a natural gas producer focused on the Marcellus Shale, on the sale of substantially all its gas production and midstream assets to Greylock Energy, an affiliate of ArcLight Capital Partners
Brookfield Canada Office Properties
Advised the Special Committee of Brookfield Canada Office Properties, Canada’s pre-eminent office real estate investment trust, on its go private transaction with Brookfield Property Partners L.P.
Concordia International Corp
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
US rights to Toprol-XL (AstraZeneca)
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
Bionomics Limited
Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.
Whistler Blackcomb Holdings Inc.
Advised Whistler Blackcomb Holdings Inc., a 75% owner and operator of the largest and most visited mountain resort in North America, on its sale to Vail Resorts, Inc.
BioD, LLC
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.
US rights to an authorized generic version of Adderall XR
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
US rights to 37 approved and 5 pipeline generic products
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products